secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001731122-25-001591
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine
--------------------------------------------------------------------------------

- Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.
- Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.
- CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.
- Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.
- Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/0001731122-25-001591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/e7068_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-001591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer